Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

SCP0182

Sigma-Aldrich

[D-Phe2,D-Ala6]-LH-RH

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C59H79N15O13
Peso molecular:
1206.35
UNSPSC Code:
12352209
NACRES:
NA.32

assay

≥95% (HPLC)

form

lyophilized

composition

Peptide Content, ≥72%

storage condition

protect from light

storage temp.

−20°C

Amino Acid Sequence

Glp-Phe-Trp-Ser-Tyr-Ala-Leu-Arg-Pro-Gly-NH2

Application

Luteinizing-hormone-releasing hormone (LHRH) (GnRH) is a decapeptide (pyroQHWSYKLRPG-NH2) trophic hormone that regulates the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. Various analogues have been developed using D-amino acids to increase resistance to degradation. These analogues are used as potential targeting agents in the development of chemotherapies and as possible agonists and antagonist of the LHRH receptor.

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H360

Hazard Classifications

Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

G Emons et al.
European journal of cancer & clinical oncology, 25(2), 215-221 (1989-02-01)
As a first step to investigate whether gonadotropin releasing hormone (GnRH) analogs might be able to modulate directly the proliferation of human epithelial ovarian carcinomata, we checked if binding sites for GnRH are present in these malignancies. Specific binding of
Andreas R Günthert et al.
Breast cancer research and treatment, 87(3), 255-264 (2004-11-06)
More than 50% of human breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH-R). These receptors can be used for targeted chemotherapy with agents like AN-152, in which doxorubicin is linked to analog [D-Lys6]LHRH. We compared the effects of AN-152
P J Wormald et al.
The Journal of clinical endocrinology and metabolism, 61(6), 1190-1194 (1985-12-01)
A specific, high affinity receptor for GnRH in human pituitaries obtained post mortem is described. The human pituitary GnRH receptor bound GnRH, a GnRH agonist [(D-Ala6,N alpha-MeLeu7,Pro9NEt)-GnRH], and a GnRH antagonist [Ac-D-Nal(2)1,D-alpha-Me-4-ClPhe2,D-3-Pal3,D-Arg6,D-Ala10 )-GnRH] with similar affinities (KdS of 4.81 nM
Ana M Bajo et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 9(10 Pt 1), 3742-3748 (2003-09-25)
The receptors for luteinizing hormone-releasing hormone receptor (LHRH-R) are found in >50% of human breast cancers. Doxorubicin (DOX) was linked to [D-Lys(6)]LHRH to form a cytotoxic conjugate, AN-152, which can be targeted to tumor cells expressing LHRH-R. We evaluated the
Alexandra P Kafka et al.
Biomedical chromatography : BMC, 24(2), 132-139 (2009-06-12)
A high-performance liquid chromatography (HPLC) method for assay of d-Lys(6)-GnRH contained in a microemulsion-type formulation is described. The peptide is extracted from the microemulsion matrix and quantified using a two-step gradient method. Separation from microemulsion compounds and potential peptide oxidation

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico